— Know what they know.
Not Investment Advice

Financial News

Sentiment 33.6 5412 articles 2813 bullish 1207 bearish Full Index →
📰

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They aren't just "pandemic stocks."
📰

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They aren't just "pandemic stocks."
📰

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p...
📰

VitalHub reports Q4 results

📰

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
📰

IGC Pharma reports results

📰

Moleculin Biotech reports FY results

📰

ROSEN, SKILLED TRIAL COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - BSX

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p...
📰

Theravance Biopharma reports Q4 results

📰

Mereo BioPharma Group reports FY results

📰

Chemomab Therapeutics reports Q4 results

📰

SkyPostal Strengthens Direct Access to Brazil with Integrated Infrastructure and Scalable Capacity

SkyPostal announced the expansion of its Brazil cross-border infrastructure, highlighting its multi-gateway access (VCP, GRU, REC), proprietary...
📰

PAO Group, Inc. Announces Rescission of Agreement and Departure of CEO James Schramm

OMAHA, Neb., March 19, 2026 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC:PAOG) today announced that James Schramm has resigned as Chief Executive...
XPeng Q4 Preview: Chinse EV Maker Struggling With Deliveries

XPeng Q4 Preview: Chinse EV Maker Struggling With Deliveries In 2026, Will Company Silence Critics?

Chinese electric vehicle company XPeng Inc (NYSE:XPEV) looks to win back over investors with shares down 20% in the last year when the company...
📰

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals

Both have plenty to offer investors, but one has a better outlook.
📰

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals

Both have plenty to offer investors, but one has a better outlook.
What's Going On With Accenture Stock Thursday?

What's Going On With Accenture Stock Thursday?

Accenture PLC (NYSE:ACN) on Thursday launched new AI-driven capabilities for its Adaptive Managed Extended Detection and Response (MxDR), developed...
Encompass Health Expands in Delaware With New 40-Bed Unit Pl

Encompass Health Expands in Delaware With New 40-Bed Unit Plans

EHC unveils a 40-bed inpatient rehabilitation hospital in Bear, DE, adding advanced therapy services and expanding its in-state footprint.
Encompass Health Expands in Delaware With New 40-Bed Unit Pl

Encompass Health Expands in Delaware With New 40-Bed Unit Plans

EHC unveils a 40-bed inpatient rehabilitation hospital in Bear, DE, adding advanced therapy services and expanding its in-state footprint.
Encompass Health Expands in Delaware With New 40-Bed Unit Pl

Encompass Health Expands in Delaware With New 40-Bed Unit Plans

EHC unveils a 40-bed inpatient rehabilitation hospital in Bear, DE, adding advanced therapy services and expanding its in-state footprint.
Encompass Health Expands in Delaware With New 40-Bed Unit Pl

Encompass Health Expands in Delaware With New 40-Bed Unit Plans

EHC unveils a 40-bed inpatient rehabilitation hospital in Bear, DE, adding advanced therapy services and expanding its in-state footprint.
📰

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of -374.36% and -89.29%, respectively, for the quarter ended December 2025. Do...
« Prev 1 73 74 75 76 77 81 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms